Mca-Ala-Pro-Lys(Dnp)-OH
Need Assistance?
  • US & Canada:
    +
  • UK: +

Mca-Ala-Pro-Lys(Dnp)-OH

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Mca-Ala-Pro-Lys(Dnp)-OH, a FRET substrate for angiotensin-converting enzyme 2 (ACE2), is used to monitor enzyme activity in plasma, urine, heart and lungs.

Category
Others
Catalog number
BAT-014521
CAS number
305336-82-7
Molecular Formula
C32H36N6O12
Molecular Weight
696.67
IUPAC Name
(2S)-6-(2,4-dinitroanilino)-2-[[(2S)-1-[(2S)-2-[[2-(7-methoxy-2-oxochromen-4-yl)acetyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid
Synonyms
Mca-APK(Dnp); L-Lysine, N-[2-(7-methoxy-2-oxo-2H-1-benzopyran-4-yl)acetyl]-L-alanyl-L-prolyl-N6-(2,4-dinitrophenyl)-; N-[(7-Methoxy-2-oxo-2H-chromen-4-yl)acetyl]-L-alanyl-L-prolyl-N6-(2,4-dinitrophenyl)-L-lysine; (S)-6-((2,4-dinitrophenyl)amino)-2-((S)-1-((S)-2-(2-(7-methoxy-2-oxo-2H-chromen-4-yl)acetamido)propanoyl)pyrrolidine-2-carboxamido)hexanoic acid
Appearance
Yellow Lyophilized Powder
Purity
≥95%
Density
1.4±0.1 g/cm3
Boiling Point
1059.4±65.0°C at 760 mmHg
Sequence
Mca-Ala-Pro-Lys(Dnp)
Storage
Store at -20°C
Solubility
Soluble in Acetonitrile
InChI
InChI=1S/C32H36N6O12/c1-18(34-28(39)14-19-15-29(40)50-27-17-21(49-2)9-10-22(19)27)31(42)36-13-5-7-25(36)30(41)35-24(32(43)44)6-3-4-12-33-23-11-8-20(37(45)46)16-26(23)38(47)48/h8-11,15-18,24-25,33H,3-7,12-14H2,1-2H3,(H,34,39)(H,35,41)(H,43,44)/t18-,24-,25-/m0/s1
InChI Key
INOZJECNSBDPGT-WDNCENIBSA-N
Canonical SMILES
CC(C(=O)N1CCCC1C(=O)NC(CCCCNC2=C(C=C(C=C2)[N+](=O)[O-])[N+](=O)[O-])C(=O)O)NC(=O)CC3=CC(=O)OC4=C3C=CC(=C4)OC
1. Percutaneous Interventions for Secondary Mitral Regurgitation
Mahboob Ali, Satya S Shreenivas, David N Pratt, Donald R Lynch, Dean J Kereiakes Circ Cardiovasc Interv. 2020 Aug;13(8):e008998. doi: 10.1161/CIRCINTERVENTIONS.120.008998. Epub 2020 Aug 6.
Mitral regurgitation is frequently associated with ventricular dysfunction and carries a high mortality. Guideline-directed medical therapy, surgical mitral valve repair or replacement, and, in the setting of advanced heart failure, heart transplant and left ventricular assist devices have been the mainstay of treatment. However, rapid advancement in the field has resulted in approval of edge-to-edge mitral valve repair with the MitraClip, and there are several novel catheter-based percutaneous options in clinical trials. Percutaneous options, while promising, must be deployed in patients who are most likely to benefit, and thus, understanding the pathophysiology of specific subgroups of patients with functional mitral regurgitation (eg, disproportionate versus proportionate mitral regurgitation) is key to the success of new devices. We review the pathophysiology, percutaneous therapeutic treatment options, and ongoing clinical trials for functional mitral regurgitation.
3. Doctor of nursing practice (DNP) degree in the United States: Reflecting, readjusting, and getting back on track
Linda A McCauley, Marion E Broome, Lorraine Frazier, Rose Hayes, Ann Kurth, Carol M Musil, Linda D Norman, Kathy H Rideout, Antonia M Villarruel Nurs Outlook. 2020 Jul-Aug;68(4):494-503. doi: 10.1016/j.outlook.2020.03.008. Epub 2020 Apr 16.
Background: In 2004, the American Association of Colleges of Nursing (AACN) called for all nursing schools to phase out master's-level preparation for advanced practice registered nurses (APRNs) and transition to doctor of nursing practice (DNP) preparation only by 2015. Today, five years after the AACN's deadline, nursing has not yet adopted a universal DNP standard for APRN practice entry. Purpose: The purpose of this paper is to examine the factors influencing the ability of nursing schools to implement a universal DNP standard for APRNs. Methods: Deans from top-ranked nursing schools explore the current state of the DNP degree in the US. The authors draw upon their collective experience as national leaders in academic nursing, long-time influencers on this debate, and heads of DNP programs themselves. This insight is combined with a synthesis of the literature and analysis of previously unpublished data from the AACN on trends in nursing doctoral education. Findings: This paper highlights issues such as the long history of inconsistency (in messaging, curricula, etc.) surrounding the DNP, certification and accreditation challenges, cost barriers, and more. The authors apply COVID-19 as a case study to help place DNP graduates within a real-world context for health system stakeholders whose buy-in is essential for the success of this professional transition. Discussion: This paper describes the DNP's standing in today's professional environment and advances the conversation on key barriers to its adoption. Insights are shared regarding critical next steps to ensure national acceptance of the DNP as nursing's terminal practice degree.
Online Inquiry
Verification code
Inquiry Basket